Overview

Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial

Status:
Recruiting

Trial end date:
2022-08-01

Target enrollment:

Participant gender:

Summary

This phase I/II randomized, placebo-controlled, double-blinded, single-site clinical trial is designed to investigate the effect of a prolonged course of atorvastatin versus placebo on CCM lesional iron deposition assessed by validated quantitative susceptibility mapping (QSM) MRI studies in patients who suffered a symptomatic bleed within the preceding one year.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of Chicago

Collaborator:

Johns Hopkins University

Treatments:

Atorvastatin
Atorvastatin Calcium